Companies · Biotechnology

Aruna Biomedical Inc

ATHENS · Biotechnology

Diligence memoA one-page analyst read on Aruna Biomedical Inc — recommendation, valuation, rhythm, risks.
$22.4M
Total raised · real
3
Rounds
2.5×
Latest step-up
Top 32%
Sector rank · raised
Series A
Latest stage · inferred · Fri Jul 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Aruna Biomedical Inc looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 2.66× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Dormant
  • Last raise 7.0 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Aruna Biomedical Inc is one of 4293 Biotechnology companies tracked from ATHENS. By capital raised it ranks mid-pack (ahead of 69% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$0–$1M
Issuer revenue
Rule 506(b)
Reg D exemption
81
Investors (latest)
2019-07-19
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeed · 2016-08-10 Raised $1.2M (real) Modeled valuation $52M (est)$1.2M$52MSeed2016Seed · 2016-08-10 Raised $3.7M (real) Modeled valuation $166M (est)$3.7M$166MSeed2016Series A · 2018-07-07 Raised $5.4M (real) Modeled valuation $195M (est)$5.4M$195MSeries A2018Series A · 2019-07-19 Raised $13M (real) Modeled valuation $481M (est)$13M$481MSeries A2019+$3.7M+$5.4M+$13MCumulative $24M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.2M · 2016
Seed extension$3.7M · 2016
Series A$5.4M · 2018
Series A extension$13.3M · 2019

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$480.5M
Base estimate est.
$14.5M
Conservative case
$2.6B
Upside case
$60.4M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $51.5M · 2016-08-102016Seed · modeled $165.8M · 2016-08-10Series A · modeled $194.5M · 2018-07-07Series A · modeled $480.5M · 2019-07-192019
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
7.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
12 mo
Avg between rounds
$7.6M/yr
Capital velocity
9.9 yr
On record since
2016
First round
4
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 3.1× above median
This company$22.4M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 2.4× above median
This company$13.3M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 7.5× above median
This company$480.5M
Sector median$64.2M

Raised more than 69% of sector peers (real $). Modeled value above 83% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #10 of 216.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)TRACT Therapeutics, Inc. · Series A Raised $15.0M · modeled $542.3M (est)TechAccel, LLC · Series A Raised $15.0M · modeled $542.3M (est)Arrakis Therapeutics, Inc. · Series A Raised $28.2M · modeled $542.3M (est)Trident Labs, Inc. · Series A Raised $14.0M · modeled $506.1M (est)Meissa Vaccines Inc · Series A Raised $15.2M · modeled $503.1M (est)Vibe Bioscience Ltd. · Series A Raised $13.9M · modeled $501.1M (est)Trovagene, Inc. · Series A Raised $45.3M · modeled $488.0M (est)Taiga Biotechnologies, Inc. · Series A Raised $37.9M · modeled $485.3M (est)Equinox, Inc. · Series A Raised $34.7M · modeled $485.2M (est)Vibe Bioscience Corp · Series A Raised $13.7M · modeled $476.8M (est)Adarza BioSystems, Inc. · Series A Raised $31.5M · modeled $461.9M (est)Aruna Biomedical Inc (this company) Raised $22.4M · modeled $480.5M (est)Aruna Biomedical Inc
CompanyStageRaised · realValue · estvs peer med.
TRACT Therapeutics, Inc.Series A$15.0M$542.3M3.00×
TechAccel, LLCSeries A$15.0M$542.3M3.00×
Arrakis Therapeutics, Inc.Series A$28.2M$542.3M3.00×
Trident Labs, Inc.Series A$14.0M$506.1M2.80×
Meissa Vaccines IncSeries A$15.2M$503.1M2.78×
Vibe Bioscience Ltd.Series A$13.9M$501.1M2.77×
Trovagene, Inc.Series A$45.3M$488.0M2.70×
Taiga Biotechnologies, Inc.Series A$37.9M$485.3M2.68×
Equinox, Inc.Series A$34.7M$485.2M2.68×
Aruna Biomedical Inc this companySeries A$22.4M$480.5M2.66×
Vibe Bioscience CorpSeries A$13.7M$476.8M2.64×
Adarza BioSystems, Inc.Series A$31.5M$461.9M2.56×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.2M2016-08-10$5.8M$51.5M85%
Seed$3.7M2016-08-10$18.7M$165.8M90%
Series A$5.4M2018-07-07$24.5M$194.5M90%
Series A$13.3M2019-07-19$60.4M$480.5M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.2M2016-08-10
    • First recorded raise — entered as Seed.
    • 6 investors on this round.
  2. Seed$3.7M2016-08-10
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 3.2× larger than the prior — scaling up.
    • 14 investors on this round.
  3. Series A$5.4M2018-07-07
    • Raised again after 23 mo — slower than the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • 32 investors on this round.
  4. Series A$13.3M2019-07-19
    • Raised 12 mo later, in step with the ~14 mo sector norm.
    • Round 2.5× larger than the prior — scaling up.
    • 81 investors on this round.
Intelligence
2020 ~Q3
Modeled next raise · ~12mo cadence
$32.8M
Modeled next size est.range $21.3M$52.5M
2.5×
Last step-up
$7.6M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Al Medwar2019-07
Barry Storey2019-07
Barry William Storey2018-07
Barry W. Storey2016-08
C. William Griffin2016-08
Darren DeVore2019-07
Darren F. Devore2016-08
Darren W. DeVore2016-08
Darren William DeVore2018-07
Harold Ingalls2019-07
Harold William Ingalls2018-07
Harold W. Ingalls2016-08
John F. Mangan, Jr.2016-08
John Mangan2019-07
John William Mangan, Jr.2018-07
John W. Mangan, Jr.2016-08
Mark Sirgo2019-07
Mason Irving2019-07
Mason William Irving, III2018-07
Russell C. Lindner2016-08
Russell Lindner2019-07
Russell William Lindner2018-07
Steven Stice2018-07
Steven W. Stice2016-08
Registry & provenance

Aruna Biomedical Inc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1447734
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
CyVek, Inc.BiotechnologySeries A$22.3M$361.5Msame sector · same stage
CircuLite IncBiotechnologySeries A$22.0M$415.7Msame sector · same stage
Aviir IncBiotechnologySeries A$22.9M$361.5Msame sector · same stage
Tobira Therapeutics, Inc.BiotechnologySeries A$23.2M$513.3Msame sector · same stage
Sound Pharmaceuticals IncBiotechnologySeries A$21.6M$304.0Msame sector · same stage
TAI Diagnostics, Inc.BiotechnologySeries A$21.1M$463.8Msame sector · same stage
Merganser Biotech, Inc.BiotechnologySeries A$21.1M$473.5Msame sector · same stage
GnuBIO Inc.BiotechnologySeries A$21.0M$361.5Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Ora Biomedical, Inc.BiotechnologyPre-Seed$4.4M88%
MDNA Life Sciences, Inc.BiotechnologyPre-Seed$25.9M86%
Zura Bio LtdBiotechnologySeries D+$1.3B85%
Auxilium Biotechnologies Inc.BiotechnologySeed$9.7M85%
Tilos Therapeutics, Inc.BiotechnologySeed$135.4M84%
TeraPore Technologies, Inc.BiotechnologySeed$78.8M84%
Tyra Biosciences, Inc.BiotechnologySeries D+$2.5B84%
Armonica Technologies, Inc.BiotechnologySeries A$11.3M84%
Frequently asked
How much funding has Aruna Biomedical Inc raised?
Aruna Biomedical Inc has raised approximately $22.4M in disclosed capital across 3 recorded financing rounds, aggregated from public filings.
What is Aruna Biomedical Inc's estimated valuation?
Provath's modeled valuation for Aruna Biomedical Inc is approximately $480.5M (modeled range $14.5M–$2.6B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Aruna Biomedical Inc at?
Aruna Biomedical Inc's latest modeled financing stage is Series A. Its most recent recorded round closed around Fri Jul 19.
What does Aruna Biomedical Inc do and where is it based?
Aruna Biomedical Inc operates in the Biotechnology sector, based in ATHENS.
Explore related

See where Aruna Biomedical Inc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Aruna Biomedical Inc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.